# ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

> **NCT05889273** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **MapLight Therapeutics** · enrollment: 120 (estimated)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** ML-004 (IR)/(ER) tablet

## Key facts

- **NCT ID:** NCT05889273
- **Lead sponsor:** MapLight Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-06-01
- **Primary completion:** 2027-11
- **Final completion:** 2027-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05889273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05889273, "ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05889273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*